EntryPoint Capital’s Palisade Bio PALI Stock Holding History

EntryPoint Capital’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$164K	Sell	78,498 -997	-1%	-$1.96K	0.04%	716
2026 Q1	$139K	Buy	+79,495	New	+$145K	0.04%	682

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EntryPoint Capital's PALI Position: Q2 2026 in Review

EntryPoint Capital reduced its Palisade Bio (PALI) stake by 1.3% in Q2 2026, selling an estimated $1.96K and leaving 78,498 shares worth $164K. The position accounts for 0.04% of the portfolio, ranked #716.

EntryPoint Capital first reported a position in PALI in Q1 2026 and has held it in 2 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

EntryPoint Capital held 78,498 shares of Palisade Bio worth $164K as of Q2 2026.
EntryPoint Capital sold 997 Palisade Bio shares in Q2 2026, an estimated $1.96K.
Palisade Bio made up 0.04% of EntryPoint Capital's portfolio in Q2 2026, its #716 holding.
EntryPoint Capital first reported a position in Palisade Bio in Q1 2026 and has held it in 2 quarters since.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.